Insider Transactions in Q1 2025 at Sarepta Therapeutics, Inc. (SRPT)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 12
2025
|
Claude Nicaise |
SELL
Open market or private sale
|
Direct |
2,491
-8.22%
|
$246,609
$99.64 P/Share
|
|
Mar 12
2025
|
Claude Nicaise |
BUY
Exercise of conversion of derivative security
|
Direct |
9,746
+24.34%
|
$243,650
$25.18 P/Share
|
|
Mar 10
2025
|
M Kathleen Behrens |
BUY
Grant, award, or other acquisition
|
Direct |
2,383
+1.22%
|
-
|
|
Mar 10
2025
|
Claude Nicaise |
BUY
Grant, award, or other acquisition
|
Direct |
2,383
+10.39%
|
-
|
|
Mar 10
2025
|
Richard Barry |
BUY
Grant, award, or other acquisition
|
Direct |
2,383
+0.08%
|
-
|
|
Mar 10
2025
|
Louise Rodino Klapac Head of R&D, CSO |
BUY
Grant, award, or other acquisition
|
Direct |
8,276
+8.91%
|
-
|
|
Mar 10
2025
|
Louise Rodino Klapac Head of R&D, CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,463
-2.19%
|
$346,300
$100.13 P/Share
|
|
Mar 10
2025
|
Dallan Murray Chief Customer Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,276
+17.81%
|
-
|
|
Mar 10
2025
|
Dallan Murray Chief Customer Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,733
-5.67%
|
$373,300
$100.13 P/Share
|
|
Mar 10
2025
|
Bilal Arif Chief Tech Ops Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,276
+20.3%
|
-
|
|
Mar 10
2025
|
Bilal Arif Chief Tech Ops Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
523
-2.11%
|
$52,300
$100.13 P/Share
|
|
Mar 10
2025
|
Stephen Mayo |
BUY
Grant, award, or other acquisition
|
Direct |
2,383
+20.93%
|
-
|
|
Mar 10
2025
|
Hans Lennart Rudolf Wigzell |
BUY
Grant, award, or other acquisition
|
Direct |
2,383
+8.63%
|
-
|
|
Mar 10
2025
|
Ian Michael Estepan Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,276
+11.67%
|
-
|
|
Mar 10
2025
|
Ian Michael Estepan Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,941
-3.43%
|
$394,100
$100.13 P/Share
|
|
Mar 10
2025
|
Cristin Rothfuss EVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
8,276
+28.16%
|
-
|
|
Mar 10
2025
|
Cristin Rothfuss EVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
491
-3.68%
|
$49,100
$100.13 P/Share
|
|
Mar 10
2025
|
Michael Andrew Chambers |
BUY
Grant, award, or other acquisition
|
Direct |
2,383
+18.27%
|
-
|
|
Mar 10
2025
|
Kathryn Jean Boor |
BUY
Grant, award, or other acquisition
|
Direct |
2,383
+22.38%
|
-
|
|
Mar 10
2025
|
Deirdre P Connelly |
BUY
Grant, award, or other acquisition
|
Direct |
2,383
+31.32%
|
-
|
|
Mar 07
2025
|
Louise Rodino Klapac Head of R&D, CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,500
+6.45%
|
-
|
|
Mar 07
2025
|
Dallan Murray Chief Customer Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,500
+14.05%
|
-
|
|
Mar 07
2025
|
Ian Michael Estepan Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,500
+8.62%
|
-
|
|
Mar 07
2025
|
Bilal Arif Chief Tech Ops Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,035
-13.57%
|
$930,605
$103.7 P/Share
|
|
Mar 07
2025
|
Dallan Murray Chief Customer Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,162
-12.45%
|
$943,686
$103.7 P/Share
|
|
Mar 07
2025
|
Cristin Rothfuss EVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
1,478
-5.67%
|
$152,234
$103.7 P/Share
|
|
Mar 07
2025
|
Louise Rodino Klapac Head of R&D, CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
8,504
-5.16%
|
$875,912
$103.7 P/Share
|
|
Mar 07
2025
|
Ian Michael Estepan Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,679
-7.82%
|
$996,937
$103.7 P/Share
|
|
Mar 06
2025
|
Bilal Arif Chief Tech Ops Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
17,500
+34.13%
|
-
|
|
Mar 06
2025
|
Dallan Murray Chief Customer Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
17,500
+31.92%
|
-
|
|
Mar 06
2025
|
Louise Rodino Klapac Head of R&D, CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
17,500
+17.44%
|
-
|
|
Mar 06
2025
|
Ian Michael Estepan Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
17,500
+21.89%
|
-
|
|
Mar 04
2025
|
Louise Rodino Klapac Head of R&D, CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,704
-2.54%
|
$172,104
$101.34 P/Share
|
|
Mar 04
2025
|
Ian Michael Estepan Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,370
-2.96%
|
$138,370
$101.34 P/Share
|
|
Mar 04
2025
|
Dallan Murray Chief Customer Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,685
-7.84%
|
$170,185
$101.34 P/Share
|
|
Mar 04
2025
|
Bilal Arif Chief Tech Ops Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
514
-1.54%
|
$51,914
$101.34 P/Share
|
|
Mar 04
2025
|
Cristin Rothfuss EVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
584
-2.17%
|
$58,984
$101.34 P/Share
|
|
Mar 03
2025
|
Cristin Rothfuss EVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
391
-2.79%
|
$40,273
$103.77 P/Share
|
|
Mar 03
2025
|
Louise Rodino Klapac Head of R&D, CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
715
-1.06%
|
$73,645
$103.77 P/Share
|
|
Mar 03
2025
|
Ian Michael Estepan Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
557
-1.19%
|
$57,371
$103.77 P/Share
|
|
Mar 03
2025
|
Bilal Arif Chief Tech Ops Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
719
-4.11%
|
$74,057
$103.77 P/Share
|
|
Mar 03
2025
|
Dallan Murray Chief Customer Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
711
-3.2%
|
$73,233
$103.77 P/Share
|
|
Jan 29
2025
|
Ian Michael Estepan Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,613
-5.28%
|
$305,721
$117.51 P/Share
|
|
Jan 29
2025
|
Ian Michael Estepan Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,800
+12.97%
|
$189,600
$12.0 P/Share
|